Vorasidenib and Lomustine for Recurrent IDH-Mutant Brain Tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a combination of two drugs (vorasidenib and lomustine) for people with a specific type of recurrent brain tumor that has an IDH mutation. The goal is to see if this combination can slow tumor growth better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with ability to care for yourself and follow study visits
- Confirmed recurrent brain tumor (oligodendroglioma or astrocytoma, grades 2-4) with IDH1 and/or IDH2 mutations
- Tumor has grown back after at least one prior surgery and one prior treatment (radiation or chemotherapy)
- Normal blood counts, kidney, and liver function based on recent blood tests
- No cancer elsewhere in the body, no uncontrolled seizures, and able to swallow pills
- If of childbearing age, willing to use effective contraception during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an oral drug called vorasidenib for children and teens with a slow-growing brain tumor (Grade 2 astrocytoma or oligodendroglioma) that has an IDH1 or IDH2 mutation. The drug is taken daily and may help keep the tumor from growing, avoiding the need for immediate chemotherapy or radiation.
This trial tests whether taking vorasidenib after standard radiation and chemotherapy can help prevent low-grade IDH-mutant astrocytoma from growing back. It is for people who have completed first-line therapy and whose tumors have not progressed.
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This trial tests a new combination therapy (L19TNF plus a chemotherapy drug like temozolomide or lomustine) for people whose IDH-mutant astrocytoma or oligodendroglioma has returned after earlier chemotherapy. The goal is to see if this combination slows tumor growth safely.
This trial tests a targeted drug, vorasidenib, for people with a specific type of slow-growing brain tumor (low-grade glioma) that has come back or is still present after surgery. The drug is guided by a special PET scan to see if it reaches the tumor.
Hear when a new Brain Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.